Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 3Completed 2Recruiting 1Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Leukemia, Myeloid, Acute 23Leukemia 3Recurrence 1Neoplasm Metastasis 1Myeloproliferative Disorders 1Myelodysplastic Syndromes 1Lymphoma, T-Cell, Peripheral 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Extranodal NK-T-Cell 1Leukemia, Myeloid 1Leukemia, Lymphocytic, Chronic, B-Cell 1Higher-risk Myelodysplastic Syndrome 1Hematologic Diseases 1Dendritic Cell Sarcoma, Interdigitating 1Bone Marrow Diseases 1

Interventions

trastuzumab deruxtecan 4Cyclophosphamide 4pembrolizumab 3fludarabine 3Standard of Care 3Cisplatin 3Bevacizumab 3toripalimab 2sacituzumab govitecan 2fludarabine phosphate 2Specimen Handling 2Radiosurgery 2Pemetrexed 2Palliative Care 2Nivolumab 2Injections 2Gemcitabine 2Fulvestrant 2Fluorouracil 2130-nm albumin-bound paclitaxel 2zimberelimab 1vedolizumab 1tislelizumab 1sintilimab 1lobaplatin 1lenvatinib 1ivosidenib 1irinotecan sucrosofate 1exemestane 1eribulin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × Neoplasm Metastasis × Azacitidine × Clear all
NCT07404332 2026-02-11

5-Azacitidine Plus PD-1/PD-L1 Inhibitor With PD-1/PD-L1 Refractory Tumors

University of Iowa

Phase 1 Not yet recruiting
35 enrolled
Tumor-Agnostic

Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡